In addition, previous reports have shown that HSP90 inhibition with the N-terminal inhibitor 17-AAG leads to compensatory up-regulation of HSP27, 40 and 70 (32), which may explain the lack of clinical efficacy using 17-AAG in some cancers. This evidence concerns the gene HSP90AB1 and cancer.